2024 Annual Meeting | C25 - Motor Neuron Disease

Date Saturday 04/13/24

Time 02:30 PM - 04:30 PM MDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Stephen Goutman, MD, FAAN

Topic(s) Neuromuscular and Clinical Neurophysiology (EMG)

Learning Objectives Participants should become familiar with ALS epidemiology, clinical presentations, diagnosis, and clinical management and treatment; learn about the emerging role of genetic testing in ALS for understanding disease risk and for personalized therapeutics; and become familiar with expanded access studies.

This program is supported in part by an educational grant from Amylyx Pharmaceuticals, Inc.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Advanced Practice Provider, Medical Student

Teaching Styles Didactic, Audience Participation

Program Evaluations

Event Timeline
02:30 PM - 03:00 PM MDT	Speaker	ALS Epidemiology, Presentation, Diagnosis, and Treatment Stephen Goutman, MD, FAAN
03:00 PM - 03:30 PM MDT	Speaker	The Approach to Genetics and Genetic Testing in ALS Matthew Harms, MD
03:30 PM - 04:00 PM MDT	Speaker	The Emergence of Expanded Access Protocols in ALS Suma Babu, MD, MPH
04:00 PM - 04:30 PM MDT	Q&A	Questions & Answers Stephen Goutman, MD, FAAN, Suma Babu, MD, MPH, Matthew Harms, MD

Faculty Disclosures
Stephen Goutman, MD, FAAN	Dr. Goutman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Evidera. The institution of Dr. Goutman has received research support from National Institutes of Health. The institution of Dr. Goutman has received research support from ALS Association. The institution of Dr. Goutman has received research support from CDC. Dr. Goutman has received intellectual property interests from a discovery or technology relating to health care.
Suma Babu, MD, MPH	The institution of Dr. Babu has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for OrphAI therapeutics. The institution of Dr. Babu has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. The institution of Dr. Babu has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Uniqure Therapeutics. Dr. Babu has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Medscape. The institution of Dr. Babu has received research support from Biogen. The institution of Dr. Babu has received research support from Novartis. The institution of Dr. Babu has received research support from Ionis. The institution of Dr. Babu has received research support from OrphAI therapeutics. The institution of Dr. Babu has received research support from Denali Therapeutics. Dr. Babu has a non-compensated relationship as a Appointed Member of the Committee on ALS: Accelerating Treatments and Improving Quality of Life with National Academies of Sciences, Engineering and Medicine that is relevant to AAN interests or activities.
Matthew Harms, MD	Dr. Harms has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Harms has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Muscular Dystrophy Association. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Invitae. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Variant Bio. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amylyx. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for uniQure. Dr. Harms has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Littlepage Booth. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for O'Connor First. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Searcy Denney. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Ford, Parshall & Baker LLC . The institution of Dr. Harms has received research support from ALS Association. The institution of Dr. Harms has received research support from Ionis. The institution of Dr. Harms has received research support from ALS Finding a Cure. The institution of Dr. Harms has received research support from Target ALS.

��ɫ��

��ɫ��